Summary
Johnson & Johnson (JNJ) announced on June 9, 2015, a key addition to its Board of Directors with the appointment of Dr. Mary Beckerle. Dr. Beckerle brings significant expertise as the Chief Executive Officer and Director of the Huntsman Cancer Institute at the University of Utah, a role that underscores her deep understanding of scientific and healthcare advancements. Her appointment is investor-focused as it strengthens the Board's capabilities in areas critical to JNJ's long-term strategy, particularly within its science and technology endeavors.
Key Highlights
- 1Appointment of Dr. Mary Beckerle to the Board of Directors.
- 2Dr. Beckerle's extensive background includes leadership at the Huntsman Cancer Institute, a prominent cancer research center.
- 3Her expertise is expected to benefit the Science, Technology & Sustainability Committee of the Board.
- 4This appointment signifies a continued focus on scientific innovation and sustainability for Johnson & Johnson.
- 5The appointment is effective immediately as of the filing date.
Frequently Asked Questions
Dr. Mary Beckerle is a distinguished scientist and leader in cancer research, serving as the Chief Executive Officer and Director of the Huntsman Cancer Institute at the University of Utah. Her appointment to JNJ's Board of Directors brings valuable scientific and strategic expertise, particularly relevant to the company's focus on healthcare innovation and sustainability.
Dr. Beckerle has been appointed to serve on the Board's Science, Technology & Sustainability Committee.
As a non-employee director, Dr. Beckerle will receive compensation in accordance with the 'Director Compensation' section of Johnson & Johnson's 2015 Proxy Statement.